Teva confirms efficacy and safety of Ajovy for prevention of migraine
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
A significant proportion of healthcare professionals still tend to favor branded drugs
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The company plans to add 1700 beds by FY27 through the organic route
Subscribe To Our Newsletter & Stay Updated